BioSpace News Archive

Synthego, the genome engineering company, today announced the launch of Eclipse™, a new high-throughput cell engineering platform designed to accelerate drug discovery and validation by providing highly predictable CRISPR-engineered cells at scale through the integration of engineering, bioinformatics, and proprietary science.

Horizon Therapeutics plc (Nasdaq: HZNP) announced the publication of data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomitantly used with an immunomodulator, mycophenolate mofetil, in Arthritis & Rheumatology [doi.org/10.1002/art.41731].

Metagenomi, a gene editing company, today announced the extension and close of its Series A financing, bringing the round to a total of $75 million. This round will support the expansion of the Metagenomi team and development of the company’s therapeutic pipeline.

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph. D., chief executive officer of Gamida Cell, will present at the 20th Annual Needham Virtual Healthcare Conference

Seagen Inc. (Nasdaq: SGEN) today announced that it will report its first quarter 2021 financial results on Thursday, April 29, 2021 after the close of U.S. financial markets.

Daiichi Sankyo Company, Limited (hereafter Daiichi Sankyo) today announced the first patient has been dosed in the first-in-human phase 1/2 study of DS-1594, a selective small-molecule menin inhibitor, in adults with relapsed/refractory acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Adoption of Technology-Enabled Services and Dispensing Solutions Supports Autonomous Pharmacy Vision

HT Medical, a surgical implant company focused on the development of novel science-based solutions for patients requiring spinal fusion surgery, today announced that it has changed its name to Xēnix Medical as part of a rebranding initiative.

Strong balance sheet: Approximately $110 million in cash and cash equivalents as of March 31, 2021 1 Company remains on-track for potential product approvals in US in August 2021 and in Europe in early 2022

Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has secured $55 million from a syndicate of leading life science investors in an oversubscribed financing round.